AOD-9604: what the research says. | Reddit

AOD-9604 is a synthetic peptide corresponding to the C-terminal region of human growth hormone, amino acids 177 to 191, with an additional tyrosine residue at the N-terminus. That definition comes from the analytical chemistry literature rather than from a vendor page: a 2015 paper in Drug Testing and Analysis describing detection methods defines the molecule exactly that way (PMID 25208511).

It entered the record as an obesity candidate. A 2004 pipeline note in Current Opinion in Investigational Drugs recorded that Metabolic was developing AOD-9604 for the potential treatment of obesity, with Phase IIa trials underway by February 2002 (PMID 15134286).

No. Human growth hormone is a 191-amino-acid protein. AOD-9604 is a short piece of its tail end with one residue added. The stated design idea, as the 2015 detection paper puts it, is that the fragment is reported to mimic the lipolytic properties of growth hormone without its diabetogenic side effects (PMID 25208511). Note the framing in that sentence: reported, not demonstrated.

It is also frequently grouped with growth-hormone secretagogues such as sermorelin or ipamorelin. Those act on the pituitary to prompt the body’s own growth hormone release. AOD-9604 is a fragment of the hormone itself, so the grouping describes a marketing shelf rather than shared pharmacology.

The proposed mechanism is direct action on fat tissue rather than on appetite. Every strand of support for it comes from rodents or from cells in a dish, so each item below is worth reading with its model attached.

This is the whole primary-research picture for AOD-9604, laid out with the model each result came from. It is a short table, and that is the point.

This is the part most pages selling it leave out. A PubMed search re-resolved against the NCBI API on 2026-07-25 returned ten records for AOD-9604, and none of them reports results from human subjects. Three are review articles about obesity drug development that mention it among other candidates, which is why an automated filter can tag them as human literature. A review naming a compound is not a trial of it.

The closest thing to a human data point in the record is administrative: the 2004 note that Phase IIa trials were underway by February 2002 (PMID 15134286). A trial being underway is not a result. Reviews of obesity drugs in clinical development from 2006 and 2007 surface in the same search (PMID 16625817), and no approved product for the compound exists in the United States today.

In rodents, the published studies report reductions in body weight and body fat. In people, there is no published trial to answer the question from. Those two sentences are the honest whole of it, and the gap between them is where most marketing copy about this peptide lives.

There is no approved dose, because there is no approved indication and no published human study to derive one from. The only dose figures traceable to peer-reviewed work are animal doses, and they are listed here as a description of the literature rather than as guidance.

No. A standard dose is the output of a dose-finding program that publishes its results, and no such program has published results for this compound. Any number presented as the dose is an extrapolation from rodents, an inheritance from another vendor page, or an invention.

There is no controlled human safety data for AOD-9604. That is a statement about missing evidence, not a safety claim, and it is the reverse of how the compound is usually presented. Unknown and safe are different words.

Avoiding the glucose effects of growth hormone was the stated point of the molecule, and the analytical literature describes that as a reported property rather than a demonstrated one (PMID 25208511). The measurements behind it are animal measurements.

Yes. A 2015 paper in Drug Testing and Analysis states that AOD9604 may be used as a performance-enhancing drug and is banned by the World Anti-Doping Agency. The same paper records that the peptide is available on several internet websites and was identified in confiscated vials in the USA (PMID 25208511).

Not on that particular assay. A 2013 paper reported that AOD-9604 does not influence the WADA growth hormone isoform immunoassay (PMID 24124033), so the test built to catch growth hormone doping does not flag it. Anti-doping labs answered with a purpose-built method instead: the 2015 paper validated a solid-phase extraction approach specifically to detect the peptide in athletes (PMID 25208511).

Being invisible to one assay is not the same as being undetectable, and it is certainly not the same as being permitted.

AOD-9604 is not an FDA-approved drug. It carries no approved indication for obesity, for joints, or for anything else in the United States.

The compounding question is more specific than legal or illegal. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication qualifies for the statute’s exemptions only if the bulk substance it is made from has a USP monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A Bulks List. A substance meeting none of those three is not banned by name. Compounding it falls outside the exemptions, which makes the resulting product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture, not a criminal prohibition, and the distinction matters when you read a vendor claiming the compound is legal.

Substances reach that list through a public nomination and review process, with the Pharmacy Compounding Advisory Committee advising the agency (Federal Register, 2024). Status can move through that process, so a statement about today is not a permanent verdict on the molecule.

From research-chemical vendors. The 2015 detection paper records the peptide as available on several internet websites and identified in confiscated vials in the USA (PMID 25208511). No prescriber, licensed pharmacy or regulator sits anywhere in that chain, so identity, purity and concentration arrive unverified.

Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

Both are described as fat-loss peptides, which is where the similarity stops. The difference that matters to a buyer is the depth of the evidence behind each and what happens when you try to obtain one.

If the underlying goal is body composition, metabolic health or resilience as you age, there are therapies a licensed physician can prescribe and a licensed US pharmacy can prepare. That is a materially different proposition from a research chemical of unverified contents.